Physician profile
Nirav Patel
NPI 1265783815
$7,366.97
in general payments reported to CMS, 2019-2025
28 companies · $4,359 in 2025
The $4,359 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $138 · 2021: $196 · 2022: $197 · 2023: $1,058 · 2024: $1,186 · 2025: $4,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,252 · Food and Beverage: $2,961 · Travel and Lodging: $325 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,252.00 |
| Food and Beverage | $2,961.18 |
| Travel and Lodging | $325.24 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $3,826.35 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $602.16 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $601.70 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Smith+Nephew, INC. | $293.77 | 2021-2024 | Grafix Pl |
| Lilly USA, LLC | $254.43 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $229.50 | 2021-2025 | |
| Saluda Medical Americas, INC. | $152.69 | 2025 | Evoke |
| Novartis Pharmaceuticals Corporation | $151.57 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.14 | 2023-2025 | Jardiance |
| Amarin Pharma, INC. | $137.75 | 2020 | |
| Glaxosmithkline, LLC. | $130.37 | 2023 | Arexvy, Trelegy Ellipta |
| Biotronik Nro, INC. | $128.94 | 2024 | Prospera |
| Kci USA, INC. | $111.14 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $81.51 | 2024-2025 | |
| Abbott Laboratories | $77.47 | 2022-2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $75.86 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Exact Sciences Corporation | $51.22 | 2023-2025 | Cologuard Collection Kit |
| Cequr Corporation | $49.72 | 2023-2024 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $46.21 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $45.31 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $30.97 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $30.65 | 2022-2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $27.00 | 2024-2025 | |
| Astellas Pharma US INC | $21.99 | 2023 | Myrbetriq |
| Intuitive Surgical, INC. | $19.00 | 2023 | Da Vinci Surgical System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.09 | 2023 | Lifevest |
| Si-Bone, INC. | $14.69 | 2023 | |
| Phathom Pharmaceuticals, INC. | $6.77 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.